CDX2 Monoclonal Antibody
-
中文名稱：CDX2鼠單克隆抗體
-
貨號：CSB-MA437110
-
規(guī)格：￥2621
-
其他：
產(chǎn)品詳情
-
產(chǎn)品描述：CDX2單克隆抗體（CUSABIO貨號：CSB-MA437110）是針對腸道特異性轉(zhuǎn)錄因子CDX2研發(fā)的高特異性科研試劑，該抗體可精準識別人類、猴類及小鼠樣本中CDX2蛋白的表位。CDX2作為調(diào)控腸道上皮細胞分化和成熟的關(guān)鍵分子，在維持腸道穩(wěn)態(tài)及腫瘤發(fā)生研究中具有重要價值，尤其在結(jié)直腸癌等消化道腫瘤的分子機制研究中被廣泛關(guān)注。本產(chǎn)品經(jīng)嚴格驗證適用于多種實驗場景，包括Western Blot檢測蛋白表達水平、免疫細胞化學（ICC）定位胞內(nèi)分布、免疫沉淀（IP）富集目標蛋白以及ELISA定量分析，其高親和力特性確保在復雜樣本中仍能保持優(yōu)異信號特異性。科研人員可將其應用于腸道發(fā)育調(diào)控機制解析、腫瘤標志物篩選、轉(zhuǎn)基因動物模型驗證等基礎研究領(lǐng)域，為消化道疾病相關(guān)信號通路研究提供可靠工具。該雜交瘤來源的單抗產(chǎn)品采用國際標準工藝生產(chǎn)，具備批次穩(wěn)定性和高重復性，滿足分子生物學、細胞生物學等多學科研究需求。
-
別名：Caudal type homeo box 2; Caudal type homeo box transcription factor 2; Caudal type homeobox 2; Caudal type homeobox protein 2; caudal type homeobox transcription factor 2; Caudal-type homeobox protein 2; CDX 2; CDX 3; CDX-3; Cdx2; CDX2_HUMAN; CDX3;
-
宿主：Mouse
-
反應種屬：Human,Monkey,Mouse
-
免疫原：Purified recombinant Human CDX2 protein fragments expressed in E.coli
-
免疫原種屬：Homo sapiens (Human)
-
克隆類型：Monoclonal
-
抗體亞型：lgG2b
-
純化方式：Affinity purified
-
克隆號：13C7
-
濃度：It differs from different batches. Please contact us to confirm it.
-
產(chǎn)品提供形式：Purified mouse monoclonal in PBS(pH 7.4)containing with 0.2% sodium azide,50% glycerol.
-
應用范圍：ELISA,WB,ICC,IP
-
推薦稀釋比：
Application Recommended Dilution WB 1:500-1:5000 ICC 1:50-1:200IP:1:200-1:2000 -
Protocols：
-
儲存條件：Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期：Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
-
用途：For Research Use Only. Not for use in diagnostic or therapeutic procedures.
產(chǎn)品評價
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-
